Effects of in vivo CXCR4 blockade and proteasome inhibition on bone marrow plasma cells in HLA-sensitized kidney transplant candidates
Open Access
- 4 March 2023
- journal article
- research article
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (6) , 759-775
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (AR070549)
- Sanofi US
- U.S. Public Health Service (R01AI154932)
This publication has 58 references indexed in Scilit:
- The role of autophagy in plasma cell ontogenesisAutophagy, 2013
- Autophagy inhibitor Lys05 has single-agent antitumor activity and reproduces the phenotype of a genetic autophagy deficiencyProceedings of the National Academy of Sciences, 2012
- Human bone marrow hematopoietic stem cells are increased in frequency and myeloid-biased with ageProceedings of the National Academy of Sciences, 2011
- Desensitization Protocols and Their OutcomeClinical Journal of the American Society of Nephrology, 2011
- Preexisting Donor-Specific HLA Antibodies Predict Outcome in Kidney TransplantationJournal of the American Society of Nephrology, 2010
- Selective Enhancement of Donor Hematopoietic Cell Engraftment by the CXCR4 Antagonist AMD3100 in a Mouse Transplantation ModelPLOS ONE, 2010
- Bortezomib Provides Effective Therapy for Antibody- and Cell-Mediated Acute RejectionTransplantation, 2008
- Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cellsExpert Opinion on Biological Therapy, 2008
- CXCL12/CXCR4 signaling promotes human thymic dendritic cell survival regulating the Bcl-2/Bax ratioImmunology Letters, 2008
- Sem1, the yeast ortholog of a human BRCA2-binding protein, is a component of the proteasome regulatory particle that enhances proteasome stabilityJournal of Cell Science, 2004